The Food and Drug Administration has granted traditional approval to Calquence with bendamustine and Rituxan for some ...

AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

A new study explores PET-guided risk stratification to tailor salvage therapy in pediatric relapsed/refractory Hodgkin ...